Benitec Biopharma
BNTC
1 hedge funds and large institutions have $1K invested in Benitec Biopharma in 2017 Q1 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
67% less funds holding
Funds holding: 3 → 1 (-2)
100% less capital invested
Capital invested by funds: $414K → $1K (-$413K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$389K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| – | -$389K | -998 | Closed |
|
|
3
Citadel Advisors
Miami,
Florida
| – | -$25K | -63 | Closed |
|
BNTC Hedge Fund Activity: Q1 2017 in Review
1 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q1 2017, worth a combined $1K — down 100% from $414K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BNTC and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Sabby Management, exiting entirely with an estimated $389K sold.
- 1 institutional investor held Benitec Biopharma (BNTC) as of Q1 2017, down from 3 in Q4 2016.
- Funds reported $1K of Benitec Biopharma stock for Q1 2017, down 100% quarter-over-quarter.
- 0 funds opened new Benitec Biopharma positions in Q1 2017 and 2 closed out, a net change of -2 holders.
- The largest Benitec Biopharma seller in Q1 2017 was Sabby Management, an estimated $389K sold.
Based on aggregated 13F filings for Q1 2017.